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ABSTRACT:  
PURPOSE. TO explain the conflicting reports about the influence of plasminogen activator inhibitor type (PAI-1) 
on pathologic angiogenesis, such as occurs during the exudative form of age-related macular degeneration. 
METHODS. The expression of PAI-1 mRNA was analyzed in human and murine choroidal neovascularization 
(CNV) by RT-PCR. The influences of increasing doses of recombinant PAI-1 were evaluated by daily 
intraperitoneal injections in PAI-1-/-and wild-type animals with a model of laser-induced CNV. The double 
mechanism of action of PAI-1 (proteolytic activity inhibition versus vitronectin binding) was explored by 
immuno-histochemical localization of fibrinogen/fibrin and by injection of recombinant PAI-1 protein defective 
for vitronectin binding or with adenoviral vectors bearing a mutated binding-deficient PAI-1 gene. 
RESULTS. PAI-1 expression was present in human CNV and strongly induced in the course of experimental 
subretinal neovascularization. Daily injections of recombinant PAI-1 proteins in control and PAI-1-/- animals 
demonstrated that PAI-1 could exhibit pro- and antiangiogenic effects, dependent on the dose. PAI-1 mutants 
defective for vitronectin binding were used to show that PAI-1 promotes choroidal pathologic angiogenesis 
merely through its antiproteolytic activity. 
CONCLUSIONS. These observations may help to reconcile reports with opposite results regarding the effects of 
PAI-1 on angiogenesis and certainly warn against uncontrolled use of PAI-1-modulating drugs in clinical trials.  
 
Several studies have demonstrated that the absence of plasminogen activator inhibitor type I (PAI-1) in 
genetically modified (knockout) mice prevents the development of tumoral angiogenesis.1,2 PAI-1, through its 
inhibition of uPA (urokinase-type plasminogen activator) and tPA (tissue-type plasminogen activator) is a key 
regulator of the plasminogen system, a proteolytic cascade implicated in various physiological and pathologic 
processes including vascular thrombolysis, inflammation, wound healing, tumor invasion, and 
neovascularization.3-6 Also, through its capacity to interact with uPAR (uPA cellular receptor), vitronectin, and 
integrins, PAI-1 may also control cell migration.7,8
That PAI-1 presence was a necessary condition for angiogenesis was also observed in a model of laser-induced 
murine choroidal neovascularization (CNV). This model, while not associated with abnormal deposit component 
(drusen), encompasses several features of the exudative form of age-related macular degeneration (AMD), such 
as the trauma at the level of the Bruch's membrane, the involvement of mononuclear cells, the choroidal origin of 
new vessels and similar angiographic aspects.9,10 Analysis of corneal angiogenesis models induced by basic 
fibroblast growth factor corroborated the resistance of PAI-1-/- mice to neovascularization.2
By contrast, others groups have in different experimental settings paradoxically suggested an inhibitory effect of 
high levels of PAI-1 on angiogenesis. Tumor cells transduced with PAI-1 cDNA showed a reduction in primary 
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tumor growth and tumor-associated angiogenesis.11 The inhibitory effect of angiostatic steroids on 
neovascularization was attributed to a decrease in the expression of uPA (urokinase-type plasminogen activator) 
and an increase in the expression of PAI-1.12-14 The efficiency of one of these compounds (anecortave acetate) in 
inhibiting human CNV is currently the subject of phase II and phase III clinical trials involving hundreds of 
patients (Slakter JS, Singerman LJ, Yannuzzi LA, Russell SR, Hudson HL, Jerdan J, Zilliox P, Robertson S, 
ARVO Abstract 2909, 2002). Curiously, initial data suggest that whereas the smaller dosage of anecortave (15-
mg periocular injection) seems much more efficient than placebo, the higher dose (30-mg injection) is 
ineffective.15 A biphasic dose-response curve was indeed observed in different in vitro (aortic rings) and in vivo 
(synthetic basements membrane [Matrigel; BD Labware, Bedford, MA] and chick chorioallantoic membrane 
[CAM] assays) models.16-18 One explanation that reconciles these apparently conflicting results suggests that 
PAI-1 may have both pro- and antiangiogenic activities, depending on its concentration. 
To test that hypothesis in vivo in a model of pathologic angiogenesis more relevant to ocular disease, we first 
evaluated the presence or absence of PAI-1 mRNA in human CNV membranes, and then assessed the spatial and 
temporal expression profiles in murine laser-induced CNV. In the second phase, the influence of experimentally 
manipulated PAI-1 levels on murine CNV was explored, using daily intraperitoneal injections of recombinant 
PAI-1. Finally, we used an adenoviral delivery system to deliver mutated PAI-1 with defective vitronectin 
binding and normal proteolytic function, to dissect the mechanism of PAI-1 activity. 
MATERIALS AND METHODS 
RT-PCR Analysis of Human and Murine Neovascular Membranes 
The methods conformed to the tenets of the Declaration of Helsinki for research involving human subjects. 
Submacular CNV specimens were completely removed during surgery for 360° macular translocation in patients 
with exudative AMD that was not amenable to conventional laser or photodynamic therapy. The specimens were 
immediately frozen in liquid nitrogen and stored at -80°C until RT-PCR analysis. 
At selected intervals (days 3-40) after laser induction in mice (described later), choroidal neovascular 
membranes and adjacent neural retina intact regions were separately extracted from frozen sections by laser 
capture microdissection (laser pressue catapulting [LPC] technique) as previously described.10 The specimens 
were covered with 100 µL lysis buffer, and total RNA isolation was performed with a kit (PUREscript RNA 
Isolation Kit; BIOzym, Landgraaf, The Netherlands), according to the manufacturer's protocol. 
The frozen murine and human tissues were first pulverized using a dismembrator (B. Braun Biotech 
International, GmBH, Melsungen, Germany) and total RNA was extracted with a kit (RNeasy; Quiagen, Paris, 
France) according to the manufacturer's protocol. 28S rRNA was amplified with an aliquot of 10 ng of total 
RNA, with a reverse transcriptase RNA PCR kit (GeneAmp Thermostable rTth; Applied Biosystems, Foster 
City, CA) and two pairs of primers (identical for human and murine; sense:  
5'-GTTCACCCACTAATAGGGAACGTGA-3' and reverse: 5'-GGATTCTGACTTAGAGGCGTTCAGT-3' for 
28S mRNA; and sense: 5'-AGGGCTTCATGCCCCACTTCTTCA-3' and reverse: 5'-AGTAGAG-
GGCATTCACCAGCACCA-3' for PAI-1 (Eurogentec, Liège, Belgium). Reverse transcription was performed at 
70°C for 15 minutes followed by a 2-minute incubation at 95°C for denaturation of RNA-DNA heteroduplexes. 
Amplification (33 cycles for PAI-1 and 19 cycles for 28S, or 45 cycles for PAI-1 and 35 cycles for 28S in the 
case of LPC material) started by a cycle of 15 seconds at 94°C, 20 seconds at 60°C and 10 seconds at 72°C. RT-
PCR products were resolved on 2% agarose gels and analyzed with a fluorescence imager (Fluor-S MultiImager; 
Bio-Rad, Richmond, CA) after staining with ethidium bromide (FMC BioProducts, Philadelphia, PA). The 
expected size for RT-PCR products was 212 bp for 28S and 197 bp for PAI-1. 
Murine Model of Laser-Induced Choroidal Neovascularization 
Homozygous PAI-1-deficient mice (PAI-1-/-) and the corresponding wild-type mice (WT or PAI-1+/+) of either 
sex, 2 to 4 months old, with a mixed genetic background of 87% C57BL/6 and 13% 129 strain, were used 
throughout the study.19 The animals were maintained with a 12-hour light-dark cycle and had free access to food 
and water. Animal experiments were performed in compliance with the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research. 
CNV was induced in mice by four burns (usually at the 6, 9, 12, and 3 o'clock positions around the optic disc) 
with a green argon laser (532 nm, 50-µm diameter spot size; 0.05-second duration, 400 mW) as previously 
described.20 Mice with hemorrhaging or that did not exhibit an evident bubble at the site of every laser impact 
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(the sign of a ruptured Bruch's membrane) were excluded from further analysis. Included animals (five or more 
in each condition) were killed at day 14 (except for spatial and temporal mRNA profiles). Before death, 
fluorescein angiograms (intraperitoneal injection of 0.3 mL of 1% fluorescein sodium; Ciba, Mechelen, 
Belgium) were performed to confirm that laser burns were showing late-phase increasing hyperfluorescent spots 
(corresponding to the leakage of fluorescein from newly formed permeable capillaries). The eyes were then 
enucleated and either fixed in buffered 3-5% formalin solution for routine histology or embedded in optimal 
cutting temperature compound (Tissue TeK; Miles Laboratories, Naperville, IL) and frozen in liquid nitrogen for 
cryostat sectioning. CNV was quantified as previously described.9,10 Briefly, frozen serial sections were cut 
throughout the entire extent of each burn, and the thickest region (minimum of five per lesion) selected for the 
quantification. Using a computer-assisted image-analysis system (Micro Image version 30 for Windows 95/NT; 
Olympus Optical Co. Europe GmbH, Birkeroed, Denmark), we estimated neovascularization by the ratio (B/C) 
of the thickness from the bottom of the pigmented choroidal layer to the top of the neovascular membrane (B) to 
the thickness of the intact-pigmented choroid adjacent to the lesion (C). A mean B/C ratio was determined for 
each laser impact. 
Immunohistochemistry 
Cryostat sections (5 µm thick) were fixed in paraformaldehyde 1% in 0.07 M phosphate-buffered saline (PBS; 
pH 7.0) for 5 minutes or in acetone for 10 minutes at room temperature and then incubated with the primary 
antibody. Antibodies raised against mouse platelet endothelial cell adhesion molecule (PECAM; rat monoclonal, 
diluted 1:20; PharMingen, San Diego, CA), and murine fibrinogen/fibrin (diluted 1:400, goat polyclonal 
antibody; Nordic Immunologic, Tilburg, The Netherlands) were incubated for 1 hour at room temperature. The 
sections were washed in PBS (three times, 10 minutes each) and appropriate secondary antibody conjugated to 
horseradish peroxidase (HRP), or tetramethylrhodamine isothiocyanate (TRITC) were added: rabbit anti-goat 
IgG (diluted 1/100; Dako, Glostrup, Denmark) and rabbit anti-rat IgG (diluted 1/40; Sigma-Aldrich, St. Louis, 
MO) were applied for 30 minutes. For immunostaining of fibrinogen/fibrin, a drop of 3-amino-9-ethylcarbazole 
(AEC+; Dako) was added, and sections were counterstained for 1 minute in hematoxylin. For 
immunofluorescence staining, after three washes in PBS for 10 minutes each and a final rinse in 10 mM Tris-
HCl buffer (pH 8.8), labeling was analyzed under an inverted microscope equipped with epifluorescence optics. 
Specificity of staining was assessed by substitution of nonimmune serum for primary antibody (not shown). 
Characterization of Active Recombinant PAI-1 and Mutants 
A stable PAI-1 variant referred to as PAI-1-stab, harboring the mutations Asnl50His, Lysl54Thr, Gln301Pro, 
Gln319Leu, and Met354Ile and demonstrating a functional half-life of approximately 150 hours, was produced 
as described21 and used in all experiments in which active recombinant PAI-1 was indicated. The mutant PAI-l-
stab-Q123K (with impaired vitronectin binding properties), was created by a method based on a mutagenesis kit 
(Quickchange Site-Directed Mutagenesis Kit; Stratagene, La Jolla, CA) using pIGE20-PAI-stab as template and 
the appropriate synthetic oligonucleotide (i.e., 5'-CGGTCAAGAAAGTG-GACTTTTCAGAGG-3', and its 
complementary oligonucleotide) for introduction of the Q123K mutation. PAI-1-stab and its variant were 
expressed and purified as described.22 Binding of PAI-l-stab-Q123K to murine vitronectin was 40 times lower 
than that observed with PAI-1-stab. WT and PAI-l-/- mice were injected intraperitoneally daily with 10 or 100 µg 
rPAI-1 or 100 µg PAI-l-stab-Q123k. 
Adenovirus-Mediated PAI-1 cDNA Transfer 
El-deleted recombinant adenovirus vectors expressing wild-type human PAI-1 (AdCMVPAI-1) or no transgene 
(AdRR5) were propagated as described previously.23,24 Recombinant viruses expressing mutant PAI-1 proteins 
AdCMVPAI-1Q123K were generated after substitution of a restriction fragment containing the desired mutation 
into the pACM-VPAI-1 (wild type; WT) shuttle plasmid. PAI-1 with the Q123K mutation had a specific 40-fold 
decrease in affinity for vitronectin, but retained full plasminogen inhibitory activity. 
One day after CNV induction by laser, mice were intravenously injected with 200 µL of control or recombinant 
adenovirus (7 X 10s plaque-forming units; PFU) encoding human PAI-1 (WT or mutant Q123K). The efficiency 
of transduction was evaluated with ELISA measurement of circulating PAI-1 levels and injection of 
adenoviruses encoding Escherichia coli β-galactosidase, as previously described (not shown).9,25 On day 14, 
mice were killed, and eyes were excised and processed, as described earlier. According to regulatory constraints, 
the virally infected animals were permanently housed under BL3 (bio-hazard level 3) containment, and 
consequently fluorescein angiograms could not be performed. 
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FIGURE 1: RT-PCR analysis of PAI-1 mRNA expression. (A) Representative example of PAI-1 mRNA expression 
in fresh surgically extracted choroidal neovascular membranes of four patients with exudative AMD (age in 
years is shown with gender). (B) Spatial profile of PAI-1 expression evaluated by RT-PCR on LPC-extracted 
murine experimental CNV at different intervals compared with the expression in intact adjacent neural retina 
(R). Histogram corresponding to the densitometric quantification of PAI-1 mRNA normalized to the 28S signal 
at different end points (D) with a representative gel (C). The evaluation was performed on the entire posterior 
segment after the induction of multiple wounds in Bruch's membrane. 28S rRNA was used to assess the total 
amount of RNA loaded. M, molecular marker. The expected size of RT-PCR products is 197 bp for PAI-1 and 
212 bp for 28S. 
Statistical Analysis 
Data were analyzed on computer (Prism 3.0; GraphPad, San Diego, CA). The Mann-Whitney test was used to 
determine whether there were significant (P < 0.05) differences between different experimental conditions. 
RESULTS 
PAI-1 Expression Profile in Neovascular Membranes 
PAI-1 mRNA was detected in all human CNV specimens obtained during surgery (representative examples in 
Fig. 1A). Because these specimens can be mixed with RPE and/or neural retina elements, we evaluated the 
spatial distribution of PAI-1 mRNA within choroidal neovascular membranes, distinct from the adjacent retina, 
by using laser capture microdissection. We were unable to perform laser capture dissection on human specimens. 
Therefore, the procedure was used on laser-induced murine CNV membranes microdissected by LPC on frozen 
sections at different time end points (days 3-40 after laser). Evidence of PAI-1 mRNA expression was observed 
in WT mice at all time points studied (Fig. 1B), with an apparent decrease during the late stage (day 40 after 
laser treatment). The retinal specimens microdissected from neighboring intact areas remained negative for PAI-
1 mRNA throughout the study period. To define more precisely the temporal pattern of gene expression, 
semiquantitative RT-PCR analysis (normalized to 28S signal) was then applied on laser-induced murine 
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neovascular choroidal membranes at different end points (days 3- 40 after laser treatment). As shown in a 
densitometry histogram and on a representative gel (Figs. 1C, 1D), PAI-1 mRNA induction was substantial 
during the course of experimental murine CNV, with a regression to basal level after day 10 (coinciding with the 
period of CNV stabilization). 
Dose-Dependent Effect of Recombinant PAI-1 on CNV 
CNV was evaluated in WT and PAI-1-/- mice by immunostaining with anti-PECAM antibodies and, 
histologically, by measuring, on serial sections, the maximum height of the lesion above the choroidal layer 
observed in neighboring intact zones (Figs. 2A-F). CNV at the site of laser-induced trauma was very restricted or 
absent in PAI-1-/- mice (Fig. 2A), but increased with daily injections of 10 (not shown) or 100 µg recombinant 
PAI-1 protein (Fig. 2C). The opposite effect was observed with daily treatment of WT mice (Fig. 2D) with high 
doses of recombinant PAI-1 (Fig. 2F). A dose-response effect was measured with increasing concentrations of 
active recombinant PAI-1 (PAI-1-stab, 10 or 100 µg/d) in PAI-1-/- mice (Fig. 2G). In WT animals, an 
approximate 35% reduction of the B/C ratio was consistently observed when the mice were treated with high 
doses of rPAI-1 (P < 0.001) compared with placebo (vehicle alone). 
Mechanisms by which PAI-1 Promotes Choroidal Angiogenesis 
Complete absence of fibrinogen/fibrin was evident in PAI-1-/-mice, compatible with excessive fibrinolytic 
activity owing to the lack of inhibition of uPA and tPA (Fig. 3A). Fibrinogen/fibrin staining was normally 
present in the WT control (Fig. 3B), whereas massive accumulation of fibrinogen/fibrin occurred both in WT 
and PAI-1-/- mice injected with high doses of recombinant PAI-1, demonstrating a severe inhibition of the 
plasminogen activator system (Figs. 3C, 3D). 
To evaluate the relative influence of the other mechanism of action of PAI-1 (the effect on cellular migration 
through binding on vitronectin), PAI-1-/- mice were either injected with 100 µg PAI-l-stab-Q123K (IP daily 
injection), or with AdCM-VPAI-lQ123K (intravenous injection on day 1 after laser treatment). The negative and 
positive controls in each experimental group were the extreme conditions (deficient PAI-1 mice treated with 
vehicle/AdRR5 and restored WT phenotype with 100 µg PAI-1-stab/AdCMVPAI-1). Daily injection of PAI-1-
stab-Q123K completely restored the CNV pattern observed with PAI-1-stab (P = 0.73, Fig. 4A). The adenoviral 
construct that exhibited a reduced affinity for vitronectin, restored the phenotype observed in PAI-1-/- animals 
infected with AdCMVPAI-1 (P = 0.03, Fig. 4B). 
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FIGURE 2: Dose-dependent effects of PAI-1 on choroidal neovascular reaction. Histologic analysis and 
immunofluorescence of new vessels (detected in red with anti-PECAM antibodies) in PAI-1-/- and WT mice 
treated with high doses of recombinant PAI-1 or vehicle only (A-F). He-matoxylin-eosin staining of a 
representative area showing, restricted choroidal reaction at the site of laser-induced trauma in PAI-1-/- mice 
treated with vehicle only (A) and increasing restoration of CNV in PAI-1-/- animals treated with 100 µg/d active 
PAI-1 (C). On the contrary, reduced angiogenesis in WT control mice treated with high doses of active PAI-1 
(100 µg/d, F) compared with WT mice treated with vehicle injection only (D). The neovascular reaction was 
determined by evaluating the B/C ratio as described previously9,10 (G). A dose-response effect was observed with 
daily injection of active PAI-1 in PAI-1-/- mice, with the higher dose (100 µg) nearly restoring the WT pattern. In 
contrast, a significant inhibitory effect on CNV development was observed when WT mice were treated with a 
high dose of active PAI-1 (P < 0.001). Error bars, SE; the choroidal layer (ch) is indicated, and the neovascular 
area is delineated. Arrows: area of laser impact. Yellow bars refer to B and green bars to C, used for the 
calculation of mean B/C ratio for each laser impact. Original magnification, X400. 
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FIGURE 3: Immunolocalization of fibrinogen/fibrin at the site of laser-induced CNV. Frozen ocular sections from 
control PAI-1-/- (A) or WT mice (B) compared with animals treated with 100 µg recombinant PAI-1 (C, D) 
reveal the absence of fibrin (stained with AEC) in PAI-1-/-and limited amounts in WT mice contrasting with the 
accumulation of fibrin in animals treated with a high dose of recombinant PAI-1. Original magnification, X400. 
 
DISCUSSION 
The spatial and temporal profiles of PAI-1 mRNA expression reported in this study are in line with previous 
observations demonstrating the induction of PAI-1 expression in migrating endothelial cells, an expression 
limited to the ciliary epithelium in the rodent intact eye, and our own previous results immunolocalizing PAI-1 
protein to CNV.9,26,27
The consistent expression of PAI-1 in human neovascular membranes suggests a role for PAI-1 during the 
progression of the exudative form of AMD. Clinically, elevated PAI-1 levels are observed in human diabetic 
retinopathy, with minimal levels in normal retinas.28 Another potential correlation comes from the role of age as 
an independent risk factor not only for human AMD29 but also for experimental CNV.30 A senescence-dependent 
upregulation of PAI-1 expression has been reported in human vascular endothelial cells31 or fibroblasts,32 
whereas another serpin, pigment-epithelium derived factor, which is a strong inhibitor of angiogenesis,33 was 
downregulated in older RPE.34
To our knowledge, this is the first report of a dose-dependent PAI-1 effect on angiogenesis in a model related to 
pathologic conditions of the retina. By testing different concentrations of IP-injected active rPAI-1, we provide 
clear evidence for dose-dependent opposite effects of PAI-1 during CNV development. The proangiogenic effect 
of PAI-1 at low concentrations and its antiangiogenic action at high concentrations are supported by the facts 
that (1) CNV formation was inhibited in PAI-1-/- mice (Lambert et al.9 and the present study); (2) CNV formation 
was restored in PAI-1-/- mice by injecting rPAI-1, and the level of restoration was proportional to the injected 
dose; (3) injection of high dose of rPAI-1 (100 µg/day) into WT mice significantly inhibited development of 
CNV. 
The colocalization of uPA and PAI-1 on migrating endothelial26 and tumoral cells35 points out the importance of 
simultaneous production of both proteases and inhibitors and leads to the concept of "proteolytic balance." By 
protecting the extracellular matrix (ECM) against excessive degradation, PAI-1 may serve to stabilize the matrix 
scaffold required for endothelial cell migration and the coordinated assembly of endothelial cells into 
capillaries.36 Along with other adhesive glycoproteins, the deposition of fibrinogen/fibrin serves as a scaffold to 
support binding of growth factors and to promote the cellular responses of adhesion, proliferation, and migration 
during an-giogenesis.37 The intense modulation of fibrinogen/ilbrin deposition induced with variations of the 
levels of PAI-1 was demonstrated in our model of experimental CNV by immuno-histochemical localization 
(Fig. 3). 
To separate the contribution of PAI-1 protease inhibitory activity from its vitronectin-binding properties 
involved in the control of cell migration,7,8 we injected PAI-1-/- mice with recombinant mutated PAI-1 protein 
defective in vitronectin binding or with adenoviruses expressing the mutant. The injected or endogenously 
expressed mutated forms both significantly restored the choroidal pathologic reaction, indicating that 
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plasminogen activator inhibition by PAI-1 is probably the major mechanism of action involved in the promotion 
of angiogenesis. A complementary approach to demonstrate a minimal influence of vitronectin binding 
properties of PAI-1 would necessitate the induction of our experimental model in vitro-nectin-deficient mice. 
Together with our previous work demonstrating the influence of uPA, tPA, and plasminogen deficiency,38 these 
new observations nevertheless point out the importance of fibrinolysis during the development of choroidal 
neovascularization. 
Most important, our data explain, at least in part, the dose-dependent efficiency of a drug such as anecortave 
acetate, already in use in clinical trials for the exudative form of AMD. The inhibition of uPA expression is 
likely to be beneficial.38 However, increased dosage of the agent may increase local expression of PAI-1 without 
reaching the high levels necessary for the inhibition of angiogenesis. This discrepancy was indeed observed with 
the higher dosage of anecortave (30mg) that was ineffective compared with placebo.25
The existence of biphasic dose/response curves warns against uncontrolled pharmacological strategies in which 
PAI-1 agonists/antagonists are used for inhibition of CNV.39
FIGURE 4: Injection of rPAI-1, defective in vitronectin binding, restored the angiogenic phenotype. PAI-1-/- mice 
were injected either with (A) mutated PAI-1 protein (daily injection of 100 µg PAI-l-stab-Q123K) or with (B) 
recombinant adenoviruses bearing the mutated human PAI-1 gene (single intravenous injection of AdCMVPAI-
1Q123κ on day 1 after laser treatment). For each condition, appropriate positive (injection of the same dose of 
PAI-1-stab/injection of AdCMVPAI-1) and negative controls (injection of vehicle only or injection of AdRR5) 
were performed. Quantification of CNV based on image analysis with calculation of the B/C ratio for each laser 
wound revealed that the mutant proteins defective for vitronectin binding restored a B/C ratio equal (P = 0.73 in 
A) or very similar (P = 0.03 in B) to that with intact PAI-1 proteins. *P < 0.05; ***P < 0.001; error bars, SE. 
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